Company intelligence / Profile preview

PeriNess

Israel

Ownership: Private
Development stage: Other

Overview

PeriNess completed a Phase 1 trial for DNase I in male infertility and is moving to Phase 2; they are also leading exploratory clinical studies of DNase I in combination with chemotherapy, immunotherapy, and CAR T cell therapy for multiple oncology indications, including pancreatic carcinoma, large B cell lymphoma, and solid tumors. Preclinical and early clinical data suggest efficacy in reducing NETs and improving outcomes when used adjunctively.

Therapeutic areas: OncologyMen's Health
Modalities: Enzyme replacement therapyProtein
Industry: Biotech

Partnerships

Xenetic Biosciences

Beyond the preview

Go deeper on PeriNess.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PeriNess.

Explore the full profile